Abivax SA American Price, Forecast, Insider, Ratings, Fundamentals & Signals

Abivax reports 2023 financial results and operational update raised eur 500m in 2023, including a eur 130m capital increase, two structured debt financing transactions aggregating eur 150m and eur 223.3m initial public offering on the nasdaq global market sufficient funds to finance operations into q4 2025, including through the announcement of top-line data from the phase 3 abtect induction trials of obefazimod in ulcerative colitis (uc) implementation of u.s. and european operational infrastructure to progress the company's ongoing clinical and preclinical programs paris, france, april 2, 2024, 8:30 a.m. cest – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of december 31, 2023, and provided an update on the progress of its development programs.

Paris, france / accesswire / february 13, 2024 / abivax sa (euronext paris:abvx))(nasdaq:abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (uc), will be presented during the 19th congress of the european crohn's and colitis organisation (ecco) on february 21-24, 2024, in stockholm, sweden. "we are delighted that all four submitted abstracts have been accepted for presentations at ecco.

London--(business wire)--citi, acting through citibank n.a., has been appointed by abivax sa (“abivax”), to act as depositary bank for its initial public offering (the “ipo”) of abivax's american depositary shares (“adss” or “adrs”) representing its ordinary shares. abivax's adss trade on the nasdaq global market under the ticker symbol “abvx”. the company's underlying ordinary shares are listed on euronext paris under the symbol “abvx”. each ads represents one ordinary share of the company. co.

Paris, france / accesswire / october 24, 2023 / abivax sa (euronext paris:fr0012333284 - abvx) (" abivax " or the " company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the nasdaq global market by way of a capital increase of 20,325,500 new ordinary shares (the " new shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of american depositary shares (" adss "), each representing the right to receive one ordinary share, in the united states (the " u...

Paris, france / accesswire / october 20, 2023 / abivax sa (euronext paris:fr0012333284 - abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on euronext in paris ("euronext paris") as from 4:20 p.m. cest.

ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scientific Officer Conference Call Participants Thomas Smith - Leerink Partners Vikram Purohit - Morgan Stanley Julian Harrison - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to ABIVAX Conference Call to discuss 2023 Financial Results and Business Update.

Both the calendar and the pipeline saw some movement this past week. Two large IPOs launched, one of which also priced, and two sizable deals submitted new filings. Eight IPOs submitted initial filings, led by three sizable names. Mach Natural Resources is currently the only IPO scheduled for the week ahead, although some small issuers may join the calendar late.

Abivax S.A. ABVX, -2.53% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol “ABVX” from Euronext Paris, according to a filing late Wednesday.